Cargando…

Long-Term Hepatitis B Surface Antigen Profile and Seroclearance Following Antiviral Treatment: A Single-Center, Real-World Cohort Study

Hepatitis B surface antigen (HBsAg) seroclearance, an indicator of recovery from hepatitis B virus (HBV) infection, is uncommon in long-term nucleos(t)ide analog (NUC) therapy. We compared the incidence of HBsAg seroclearance in patients with and without NUC discontinuation to identify predictors of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Chih-Wen, Yang, Chen-Ta, Su, Pei-Yuan, Chen, Yang-Yuan, Huang, Siou-Ping, Yen, Hsu-Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669103/ https://www.ncbi.nlm.nih.gov/pubmed/38001966 http://dx.doi.org/10.3390/biomedicines11112966

Ejemplares similares

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis
por: Yen, Hsu-Heng, et al.
Publicado: (2022)

Cellular immune responses in patients with hepatitis B surface antigen seroclearance induced by antiviral therapy
por: Liang, Minfeng, et al.
Publicado: (2011)

Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Radiation Exposure among Patients with Inflammatory Bowel Disease: A Single-Medical-Center Retrospective Analysis in Taiwan
por: Yang, Chen-Ta, et al.
Publicado: (2022)

Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record
por: Shi, Zongqi, et al.
Publicado: (2022)

Using Machine Learning Algorithms to Predict Hepatitis B Surface Antigen Seroclearance
por: Tian, Xiaolu, et al.
Publicado: (2019)

Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance
por: Lee, Hyun Woong, et al.
Publicado: (2020)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance
por: Zheng, Ming-Hua, et al.
Publicado: (2014)

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Comparison of Adverse Events of Different Endoscopic Ultrasound-Guided Tissue Acquisition Methods: A Single-Center Retrospective Analysis
por: Lin, Yen-Chih, et al.
Publicado: (2022)

Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta‐analysis
por: Song, Aixin, et al.
Publicado: (2021)

Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses
por: Yeh, Ming-Lun, et al.
Publicado: (2011)

Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
por: Yen, Hsu-Heng, et al.
Publicado: (2020)

Immune Mechanisms Underlying Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B Patients With Viral Coinfection
por: Wu, Shuling, et al.
Publicado: (2022)

Metabolic-Associated Fatty Liver Disease, Hepatitis B Surface Antigen Seroclearance, and Long-Term Risk of Hepatocellular Carcinoma in Chronic Hepatitis B
por: Yu, Ming-Whei, et al.
Publicado: (2022)

Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B
por: Kim, Tae Hyung, et al.
Publicado: (2018)

Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance
por: Park, Yewan, et al.
Publicado: (2021)

Clinical features of chronic hepatitis B patients with low hepatitis B surface antigen levels and determinants of hepatitis B surface antigen seroclearance
por: Taniguchi, Hideaki, et al.
Publicado: (2020)

Metabolic Dysfunction-Associated Fatty Liver Disease in Taiwanese Patients with Inflammatory Bowel Disease: A Study in Patients with Clinical Remission
por: Hsiao, Shun-Wen, et al.
Publicado: (2023)

Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B
por: Hui, Ka-Yin, et al.
Publicado: (2023)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance
por: Jang, Jeong Won, et al.
Publicado: (2021)

A retrospective study of prevalence and pattern of international consensus on ANA patterns among patients with hepatitis C virus infection
por: Hsiao, Shun-Wen, et al.
Publicado: (2022)

Comparison of Machine Learning Models and the Fatty Liver Index in Predicting Lean Fatty Liver
por: Su, Pei-Yuan, et al.
Publicado: (2023)

Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: A Taiwanese retrospective cohort study
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Evaluation of HBsAg Seroclearance in Patients with Hepatitis B
por: Taşkın, Mehmet Can, et al.
Publicado: (2022)

Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China
por: He, Yaozu, et al.
Publicado: (2023)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

Strategy for the Micro-Elimination of Hepatitis C among Patients with Diabetes Mellitus—A Hospital-Based Experience
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer
por: Lou, Cheng, et al.
Publicado: (2018)

Seroclearance of hepatitis B surface antigen following hepatitis E exacerbation on chronic hepatitis E and B dual infection in a renal transplant recipient: a case report
por: Yeh, Chau-Ting, et al.
Publicado: (2018)

Machine-Learning Algorithm for Predicting Fatty Liver Disease in a Taiwanese Population
por: Chen, Yang-Yuan, et al.
Publicado: (2022)

Spontaneous Hepatitis B Seroclearance upon Development of Hepatocellular Carcinoma
por: Naimimohasses, Sara, et al.
Publicado: (2017)

Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection: A cohort study
por: Irham, Lalu Muhammad, et al.
Publicado: (2019)

Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance
por: Kim, Saein, et al.
Publicado: (2021)

Host Genetic Factors Affecting Spontaneous HBsAg Seroclearance in Chronic Hepatitis B Patients
por: Cheng, Huei-Ru, et al.
Publicado: (2013)

Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection
por: Cao, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v9l37vqs5quggt4ftmvfd4urf0